What question did this study set out to answer?

This research explores how metabolic and redox signaling operates within major depressive disorder (MDD).

February 26, 2026Open Access

Peripheral Metabolic–Redox Signaling as a Core Mechanism of Major Depressive Disorder: Evidence from Deep Metabolomic Phenotyping

Key Points

This research explores how metabolic and redox signaling operates within major depressive disorder (MDD).
Used deep metabolomic phenotyping to identify MDD metabotype.
Analyzed metabolic networks associated with the pathogenesis of MDD.
Evaluated potential drug targets related to various biochemical pathways.
Identified a cohesive metabolic network linked to the NIMETOX pathogenesis of MDD.
Highlighted lipoxygenase-15 and lipotoxicity as key factors in MDD.
Proposed phospholipase A2 and lipid-redox intersections as potential drug targets.

Abstract

The MDD metabotype represents a cohesive metabolic network that is associated with the NIMETOX pathogenesis of MDD. Metabolomics provides a comprehensive foundation for subtyping and precision psychiatry. Lipoxygenase-15, lipotoxicity, phospholipase A2, and lipid-redox intersections might be important drug targets to treat MDD.

Peripheral Metabolic–Redox Signaling as a Core Mechanism of Major Depressive Disorder: Evidence from Deep Metabolomic Phenotyping

Key Points

Abstract

Cite This Study